Article of the day, August 29th, suggested by the Immune Oncology Research Institute

Immune Oncology Research Institute shared a post on LinkedIn:

“Article of the day! Suggest by the Immune Oncology Research Institute.

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Authors: Hussein A. Tawbi, Dirk Schadendorf, Evan J. Lipson, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J. Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Arance, Jean-Jacques Grob, Shivani Srivastava, Mena Abaskharoun, Melissa Hamilton, Sarah Keidel, Katy L. Simonsen, Anne Marie Sobiesk, Bin Li, F. Stephen Hodi and Georgina V. Long.

Author Affiliations: DKFZ German Cancer Research Center, Sidney Kimmel Comprehensive Cancer Center at Jefferson, Fundación Arturo López Pérez (FALP), FAICIC Centro de Investigación Clínica, National & Kapodistrian University of Athens ,BRYSTOL MYERS SQUIBB SL, Dana-Farber Cancer Institute, et al.

Source: Immune Oncology Research Institute/LinkedIn

Immune Oncology Research Institute (IMMONC), established in 2022, is a non-profit, independent, patient-centered research institute. The mission of IMMONC is to advance the cancer knowledge and care through breakthrough scientific research, to integrate innovative immune-oncology therapies into the clinical practice for different types of cancers, to generate and collect clinical data for the identification of new therapeutic targets, developing predictive models and optimizing patient outcomes, to increase the availability and accessibility of those discoveries for the cancer patients, to create a world-class professional environment, to attract the brightest minds in cancer field and to train the next generation researchers.